CN108289970B - 包含mri造影剂的组合的制剂 - Google Patents

包含mri造影剂的组合的制剂 Download PDF

Info

Publication number
CN108289970B
CN108289970B CN201680069678.2A CN201680069678A CN108289970B CN 108289970 B CN108289970 B CN 108289970B CN 201680069678 A CN201680069678 A CN 201680069678A CN 108289970 B CN108289970 B CN 108289970B
Authority
CN
China
Prior art keywords
api
subject
mmol
pharmaceutical formulation
magnetic resonance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680069678.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108289970A (zh
Inventor
A.R.梅杰
P.J.达威尔
M.J.塔宁
C.V.格林格里
S.德塞纳
D.卡西迪
P.A.琼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of CN108289970A publication Critical patent/CN108289970A/zh
Application granted granted Critical
Publication of CN108289970B publication Critical patent/CN108289970B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CN201680069678.2A 2015-11-30 2016-11-30 包含mri造影剂的组合的制剂 Active CN108289970B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260804P 2015-11-30 2015-11-30
US62/260804 2015-11-30
PCT/EP2016/079311 WO2017093336A1 (en) 2015-11-30 2016-11-30 Formulations comprising a combination of mri contrast agents

Publications (2)

Publication Number Publication Date
CN108289970A CN108289970A (zh) 2018-07-17
CN108289970B true CN108289970B (zh) 2022-04-08

Family

ID=57442712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680069678.2A Active CN108289970B (zh) 2015-11-30 2016-11-30 包含mri造影剂的组合的制剂

Country Status (5)

Country Link
US (1) US11110185B2 (enExample)
EP (1) EP3383441A1 (enExample)
JP (2) JP7049993B2 (enExample)
CN (1) CN108289970B (enExample)
WO (1) WO2017093336A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
JP7049993B2 (ja) 2015-11-30 2022-04-07 ジーイー・ヘルスケア・アクスイェ・セルスカプ Ｍｒｉ造影剤の併用を含む製剤
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
KR102464647B1 (ko) 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
CN111712477B (zh) * 2017-12-20 2024-02-02 通用电气公司 阴离子螯合物化合物
CN108940221A (zh) * 2018-07-27 2018-12-07 福建省微生物研究所 壳聚糖磁性吸附剂除去钆塞酸二钠注射液中游离钆的方法
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
EP4041075B1 (de) * 2019-10-08 2025-08-13 Bayer Aktiengesellschaft Erzeugung von mrt-aufnahmen der leber ohne kontrastverstärkung
CN114502069A (zh) * 2019-10-11 2022-05-13 拜耳公司 加速mrt检查
EP4128261A1 (de) 2020-04-03 2023-02-08 Bayer Aktiengesellschaft Erzeugen von radiologischen aufnahmen
EP4335461A1 (en) 2022-09-09 2024-03-13 Bayer AG Combinations of contrast agents
CN118710819B (zh) * 2024-08-29 2024-11-19 电子科技大学成都学院 一种体表静脉血管3d成像方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
CA2565668A1 (en) 2004-05-04 2005-11-10 Torfinn Taxt Method of mr imaging
GB0609610D0 (en) 2006-05-15 2006-06-21 Stiftelsen Universitetsforskni MR perfusion
US8192721B2 (en) 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US12097269B2 (en) * 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
US20160045623A1 (en) * 2015-04-03 2016-02-18 Lipella Pharmaceuticals, Inc. Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)
JP7049993B2 (ja) 2015-11-30 2022-04-07 ジーイー・ヘルスケア・アクスイェ・セルスカプ Ｍｒｉ造影剤の併用を含む製剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Combined Gadoxetic Acid and Gadofosveset Enhanced Liver MRI: A Feasibility and Parameter Optimization Study";Peter Bannas等;《Magnetic Resonance in Medicine》;20150203(第75期);摘要，Fig.1，第319页 *
"History of Changes for Study: NCT02156739-Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)";M.D. Anderson Cancer Center;《clinicaltrials.gov》;20140603;第1-3页 *
Peter Bannas等."Combined Gadoxetic Acid and Gadofosveset Enhanced Liver MRI: A Feasibility and Parameter Optimization Study".《Magnetic Resonance in Medicine》.2015,(第75期),摘要，Fig.1，第319页. *

Also Published As

Publication number Publication date
US11110185B2 (en) 2021-09-07
US20180303960A1 (en) 2018-10-25
JP2019500333A (ja) 2019-01-10
CN108289970A (zh) 2018-07-17
JP7049993B2 (ja) 2022-04-07
EP3383441A1 (en) 2018-10-10
WO2017093336A1 (en) 2017-06-08
JP2022046482A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
CN108289970B (zh) 包含mri造影剂的组合的制剂
JP2019500333A5 (enExample)
TW319763B (enExample)
JP6608805B2 (ja) 造影製剤および関連する調製方法
SK4842000A3 (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US20080044358A1 (en) Methods for lymph system imaging
Di Gregorio et al. Supramolecular adducts between macrocyclic Gd (iii) complexes and polyaromatic systems: a route to enhance the relaxivity through the formation of hydrophobic interactions
EP2222346A1 (en) Mr imaging agent, imaging medium and methods of imaging wherein such an imaging medium is used
ES2297888T3 (es) Procedimiento diagnostico para la deteccion de isquemia miocardica.
AU2001273946B2 (en) Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability
KR101451446B1 (ko) 퍼플루오르화 ｐｅｇ기를 갖는 금속 킬레이트, 그의 제조 방법, 및 그의 용도
Gu et al. Gd-complexes of 1, 4, 7, 10-Tetraazacyclododecane-N, N′, N′′, N′′′-1, 4, 7, 10-tetraacetic acid (DOTA) conjugates of tranexamates as a new class of blood-pool magnetic resonance imaging contrast agents
AU2001273946A1 (en) Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability
Hasallari et al. A novel albumin-binding macrocyclic Gd-HPDO3A complex bearing a deoxycholic acid residue: the role of the hydration state, water exchange and local dynamics in the observed relaxivity
US12226494B2 (en) Pharmaceutical compositions comprising Gd-complexes and polyarylene additives
Palkowitsch et al. Summary of the safety data for gadobutrol and gadofosveset
Karwowski et al. Gadolinium Gd (III) complexes with derivatives of nitriloacetic acid: synthesis and biological properties
ITMI20001352A1 (it) Uso di derivati di acidi biliari coniugati con complessi di ioni metallici nella visualizzazione diagnostica di sistemi microvascolari ad el
Weitz Fluorinated Metal Complexes as MRI Contrast Agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: A.R.Major

Inventor after: P.J.Dawell

Inventor after: M.J.Tanin

Inventor after: C.V.Greengrid

Inventor after: S.Desena

Inventor after: D.Cassidy

Inventor after: P.A.Jones

Inventor before: A.R.Major

Inventor before: P.D.Dale

Inventor before: M.J.Tanin

Inventor before: C.V.Greengrid

Inventor before: S.Desena

Inventor before: D.Cassidy

Inventor before: P.A.Jones

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant